Press Releases

Rehovot, Israel – November 30, 2009 – Evogene Ltd. (TASE: EVGN) announced today the successful completion of its previously announced program to substantially increase the company's R&D and administrative facilities. 

During the past year, the company has developed and is now operating a new greenhouse site at Kibutz Naan, Israel for model and target plant growth. The site is comprised of 15 state of the art greenhouses with cutting edge equipment for plant validation assays.  In addition, the company completed the expansion of its existing facilities in Rehovot, which included substantial increases to all computational and lab-based components of its gene discovery and plant validation platform, including molecular biology and tissue culture, in addition to new administrative offices.   

Ofer Haviv, Evogene's President and CEO stated: "Since Evogene's formation in 2002, the company has established a powerful technology platform that enables highly accurate and rapid computational discovery and plant validation of candidate genes, linked to desired plant traits. During the past two years, we significantly increased our gene discovery and validation capabilities in terms of gene quantities and efficiency and entered into several new collaborations. In addition, during this time period we more than doubled the size of our technological team, which now consists of more than 80 persons from all the required scientific disciplines.” Ofer Haviv continued, “With the completion of this facilities expansion, we now have the facilities and equipment that will allow us to both support our existing collaboration agreements and provide us with the opportunity to pursue additional collaborations in the coming years.” 

For more information on Evogene’s new greenhouses site and platform, please click here.